Ozempic and vision loss lawsuits: separating legal claims from clinical evidence

What's this video probably claiming?

Fox 5 New York is reporting on a lawsuit filed by a Long Island man named Michael, 48, who alleges that Ozempic (semaglutide) caused him to lose partial vision. This kind of local news litigation coverage typically frames the story as: person takes drug, bad thing happens, person sues manufacturer Novo Nordisk. The implicit claim embedded in that narrative is that Ozempic caused the vision loss, or at minimum that Novo Nordisk failed to adequately warn patients about the risk. Viewers watching this clip will almost certainly walk away with the impression that semaglutide is dangerous for your eyes. That impression deserves serious scrutiny. Lawsuits allege causation; they do not establish it. The legal standard for filing a complaint is far lower than the evidentiary standard required to demonstrate that a drug causes a specific adverse event in a population.

What does the science actually show?

The condition most frequently linked to GLP-1 receptor agonists and vision problems is nonarteritic anterior ischemic optic neuropathy, or NAION, a rare but serious condition involving reduced blood flow to the optic nerve. A July 2024 study published in JAMA Ophthalmology by Hathaway et al. found that semaglutide users had a statistically higher incidence of NAION compared to non-users among patients with type 2 diabetes (hazard ratio approximately 4.28) and obesity (hazard ratio approximately 7.64). Those are not small numbers. But context matters enormously here. NAION itself affects roughly 2 to 10 per 100,000 people annually in the general population. The absolute risk remains low even with those elevated hazard ratios. Critically, this was a retrospective observational study, not a randomized controlled trial, so confounding factors including obesity, hypertension, and cardiovascular disease, all independent NAION risk factors, cannot be fully ruled out.

Where does the social media noise diverge from clinical reality?

The gap between a Fox 5 lawsuit story and clinical reality is wide. Local news litigation coverage rarely explains that the plaintiff must prove causation in court, which requires a different and far more demanding evidence threshold than epidemiological association. It also rarely mentions that semaglutide's large-scale cardiovascular outcomes trial, SELECT (Lincoff et al., 2023, NEJM), involving over 17,600 participants, did not identify vision loss as a notable adverse event. Novo Nordisk has not updated the Ozempic prescribing label to include NAION as a confirmed risk, though the FDA has been watching this closely since the Hathaway findings surfaced. Social media amplifies individual cases because they are emotionally compelling. One man losing vision is concrete. A hazard ratio in a retrospective cohort study is abstract. That asymmetry distorts public risk perception in ways that can cause real harm, including people stopping medications that genuinely reduce their risk of heart attack and stroke.

What should you actually know?

If you are currently taking semaglutide or any GLP-1 receptor agonist and are concerned about vision changes, the relevant facts are these. Sudden vision changes, blurring, or loss of peripheral vision should always prompt an immediate call to your physician regardless of what medications you are taking. NAION can occur in people who have never touched a GLP-1 drug. The Hathaway 2024 JAMA Ophthalmology findings warrant ongoing pharmacovigilance, and researchers are actively studying this. The FDA has not issued a safety communication mandating a label change as of mid-2024, but that regulatory picture may evolve. What this lawsuit does not do is prove that Ozempic caused Michael's vision loss. It alleges it. Those are different things, and conflating them in a 60-second TikTok clip does viewers a disservice.